- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03029182
Simulated-altitude to Optimize Aerobic Exercise Among Breast Cancer Survivors With Limited Mobility
Simulated-Altitude as an Adjunct to Optimize Aerobic Exercise in Obese Breast Cancer Survivors With Limited Ambulatory Function: Pilot Randomized Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cancer survivors have a two-fold greater risk of having one or more functional limitations compared to those without a history of cancer. Though exercise interventions in breast cancer survivors exist, a large portion of women (61%) exhibit some form of lower-body dysfunction that severely restricts participation in physical activity and exercise. Both physical and emotional well-being are negatively affected by the combination of increased adiposity, orthopedic problems and muscle weakness, thus reinforcing a cycle of physical inactivity.
For these reasons, obese breast cancer survivors with walking limitations are faced with a barrier that greatly increases the difficulty of meeting prescribed exercise guidelines (≥150 weekly minutes of moderate-to-vigorous intensity exercise). Though previous investigations have demonstrated the safety and benefits of exercise+simulated altitude to improve body fat, physical endurance and insulin sensitivity, results have been limited to non-cancer participants only. Given the comorbidities common to breast cancer survivors, specifically, heart disease risk, lower body joint problems, low aerobic capacity, and fatigue, further research is needed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Physician's medical clearance for participation
- English-speaking women
- 18-70 years of age with a history of Stage 0-III breast cancer
- Preferred walking speed of less than 2.9 mph as measured by a timed 10 meter walk test (to be performed on-site after consent during preliminary screening) "OR" the inability to complete a 6-minute walk without stopping (to be performed on-site after consent during preliminary screening)
- Body mass index between 30-45 kg/m2
- ≥1 year post-treatment and not currently receiving or planning to receive chemo/radiation therapies
- Not participating in a structured exercise routine
- In the previous 6 months, not engaging in (on average) ≥60 minutes of moderate or ≥30 minutes of vigorous physical activity per week.
Exclusion Criteria:
- Males
- Dementia
- Medical, psychological, and/or social characteristics that may interfere with the ability to fully participate in the proposed study activities/assessments (e.g., psychosis, schizophrenia)
- Contraindication to participate in regular exercise training
- Unwilling to complete prescribed exercise
- Inability to walk
- Pregnant
- Resting oxygen saturation via pulse oximetry below 90%
- Using home oxygen therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Walking+simulated-altitude
8-week exercise training program that involves 3 supervised, treadmill walking sessions each week with 16% oxygen, which will be administered through an exercise mask.
|
Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ.
The progression of exercise training will be based on a varying percents of heart rate reserve.
|
Active Comparator: Walking (control)
8-week exercise training program that involves 3 supervised, treadmill walking session each week.
|
Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the feasibility of an 8 week exercise intervention comparing walking+simulated-altitude to walking (control) based on retention.
Time Frame: baseline to 8 weeks
|
number of participants completing the 8 week session
|
baseline to 8 weeks
|
Determine the feasibility of an 8 week exercise intervention comparing walking+simulated-altitude to walking (control) based on adherence to exercise compliance.
Time Frame: baseline to 8 weeks
|
mean compliance among all participantswith exercise prescription
|
baseline to 8 weeks
|
Determine the feasibility of an 8 week exercise intervention comparing walking+simulated-altitude to walking (control) based on number of adverse events.
Time Frame: baseline to 8 weeks
|
Number of adverse events in each group
|
baseline to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect sizes for walking+simulated-altitude and walking (control) as measured by a 6 minute walk.
Time Frame: baseline to 8 weeks
|
6 minute walk test, a valid and reliable tool in cancer survivors will be used to evaluate cardiovascular health and mobility.
Total distance (in meters) covered over the duration of 6 minutes will be recorded.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by the cardiorespiratory fitness.
Time Frame: baseline to 8 weeks
|
Cardiorespiratory fitness, will be measured by indirect calorimetry during a graded walking test on a treadmill to estimate peak aerobic capacity.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by arterial elasticity.
Time Frame: baseline to 8 weeks
|
Arterial elasticity, will be measured by local pulse contour analyses (HDI/Pulse Wave), A non-invasive procedure based on a modified Windkessel model which permits the evaluation of vascular health.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by resting heart rate variability.
Time Frame: baseline to 8 weeks
|
Heart rate variability, will be determined by R-to-R interval variations in heart rate, used to index sympatho-vagal balance.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by the fasting glucose.
Time Frame: baseline to 8 weeks
|
Typically, a "normal" blood sugar level is identified by experts as anything less than 100 mg/dL after a period of fasting.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by C-reactive protein (mg/L) serum assays.
Time Frame: baseline to 8 weeks
|
Serum assays, will be measured following an overnight to evaluate metabolic and cardiovascular health.
Standards practices will be implemented.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by tumor-necrosis factor-alpha (pg/mL) assays.
Time Frame: baseline to 8 weeks
|
Serum assays, will be measured following an overnight to evaluate metabolic and cardiovascular health.
Standards practices will be implemented.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by interleukin-6 (pg/mL) serum assays.
Time Frame: baseline to 8 weeks
|
Serum assays, will be measured following an overnight to evaluate metabolic and cardiovascular health.
Standards practices will be implemented.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by interleukin-10 (pg/mL) serum assays.
Time Frame: baseline to 8 weeks
|
Serum assays, will be measured following an overnight to evaluate metabolic and cardiovascular health.
Standards practices will be implemented.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by body composition (% body fat).
Time Frame: baseline to 8 weeks
|
Body composition, will be measured by dual-energy X-ray absorptiometry during which participants will be scanned while lying supine in light clothing with their arms at their sides.
|
baseline to 8 weeks
|
The effect sizes for walking+simulated-altitude and walking (control) as measured by free-living physical activity.
Time Frame: baseline to 8 weeks
|
Free-living physical activity, will be measured by a triaxial accelerometer (e.g., Actigraph GT3X).
Participants will wear the accelerometer on the hip of their non-dominant side during waking periods and around the wrist when sleeping according to a previously published protocol.
|
baseline to 8 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F160215001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Walking+simulated-altitude
-
Mayo ClinicCompletedAltitude HypoxiaUnited States
-
Biofourmis Singapore Pte Ltd.Completed
-
University of ZurichCompletedPulmonary HypertensionSwitzerland
-
University of ZurichCompleted
-
Jozef Stefan InstituteUniversity of LausanneRecruitingHypoxia | Premature BirthSlovenia, Switzerland
-
University of ZurichCompletedPulmonary HypertensionSwitzerland
-
University of ZurichCompletedPulmonary HypertensionSwitzerland
-
University of ZurichCompleted
-
University of ZurichCompletedPulmonary HypertensionSwitzerland
-
University of ZurichCompleted